What are the latest funding news in the femtech market? (July 2026)
Download our beautiful pitch about the femtech market
In our femtech market deck, you will find everything you need to understand the market
The latest femtech funding activity shows a market moving beyond period care into diagnostics, devices, fertility biotech, pelvic health and AI-enabled care navigation.
Most recent rounds were early-stage, but larger raises went to clinical or regulated companies preparing for studies, launches or commercial readiness.
India, the U.S., Europe, Canada, Australia and Japan all appeared in the latest funding news, showing that femtech is becoming a globally distributed startup category.
And if you want to better understand this new industry, you can download our pitch covering the femtech market.
Insights
- Four of the 12 latest femtech deals were announced on 1 July, showing a short burst of funding news across diagnostics, pelvic health and intimate wellness
- The largest disclosed round was Mammogen’s Series A of up to $30 million, which shows investor appetite for breast health diagnostics with clear clinical use cases
- Clinical femtech companies attracted the biggest checks, while consumer femtech brands generally raised smaller seed or pre-seed rounds under $3 million
- Fertility and gynecological diagnostics stayed highly active, with Intu Diagnostics, Dioseve and Rejoni all targeting specific reproductive health pain points
- Hormone tracking is moving from apps to hardware, with Clair Health raising $11.6 million for a wearable approach to female hormone monitoring
- India appeared twice in the latest femtech funding list, with Avni Wellness and HealthFab both focused on accessible women’s health products
- AI is now present in femtech care delivery, but the clearest funding cases were women-specific platforms rather than broad health AI tools
- The latest list suggests femtech investors still prefer focused use cases, especially where the product targets a clear biological need or care pathway
As this chart shows, and as featured in our femtech market deck, search interest in femtech has increased significantly
Summary table of the latest funding deals in the femtech market as of July 2026
We define the femtech market as technology-enabled products and services that address women’s reproductive and other female-specific health needs.
We include solutions focused on menstrual and cycle health, fertility and contraception, pregnancy and postpartum, menopause, pelvic and sexual health, and clinically oriented tools for conditions that predominantly or uniquely affect women, such as breast and gynecological cancers.
We exclude general-purpose health, wellness, fitness, mental health, and consumer apps that are not specifically designed around women’s biology, care pathways, or life stages.
You can also read our detailed analysis to understand how funding activity in the femtech market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the femtech market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Avni Wellness | 8 July 2026 | $0.47M | Seed | Menstrual, hormonal, menopause, vaginal and urinary health products |
| Materna Medical | 1 July 2026 | $5.00M | Series B3 | Maternal health and pelvic-health medical devices |
| Intu Diagnostics | 1 July 2026 | $1.29M | Bridge | HPV and cervical cancer diagnostics |
| Mila | 1 July 2026 | $2.50M | Pre-seed | Female intimate and sexual wellness |
| Rejoni | 1 July 2026 | $25.00M | Undisclosed financing | Uterine healing and pelvic health |
| Ovum | 24 June 2026 | $4.00M | Seed | Women’s health AI and longitudinal female health data |
| June Health | 18 June 2026 | $1.76M | Undisclosed funding round | Women’s health care navigation and virtual care |
| Clair Health | 17 June 2026 | $11.60M | Seed | Continuous hormone monitoring wearable |
| Dioseve | 17 June 2026 | $7.00M | Extended Series A | Fertility biotech and IVF lab technology |
| Mammogen | 10 June 2026 | Up to $30.00M | Series A | Breast cancer RNA blood diagnostics |
| Joyvié Health | 5 June 2026 | $1.04M | Pre-seed | Continence underwear and pelvic-health care products |
| HealthFab | 4 May 2026 | $2.40M | Series A | Menstrual hygiene and period-care products |
All the latest funding deals during in the femtech market as of July 2026
Avni Wellness raised $0.47 million in seed funding in July 2026
When was it?
The Avni Wellness seed round was announced on 8 July 2026.
Who are they?
Avni Wellness sells women’s health products for menstrual, hormonal, urinary, vaginal, PCOS, iron-deficiency and menopause-related needs.
Geographical focus?
Avni Wellness is focused on India, especially through digital commerce, online marketplaces and women-led micro-entrepreneur channels.
Why do we include them in the femtech market?
Avni Wellness belongs in the femtech market because the portfolio is built around female-specific menstrual, hormonal, menopause, vaginal and urinary health needs.
What is the company stage?
Avni Wellness is an early-growth company with real products in market and plans to scale digital commerce.
How much did they raise?
Avni Wellness raised about $0.47 million for this seed round.
What round is it?
The Avni Wellness financing was a seed round.
Why did they raise?
Avni Wellness raised to strengthen digital commerce, expand cycle nutrition products, grow its women-led network and increase marketplace presence.
Materna Medical raised $5 million in B3 financing in July 2026
When was it?
The Materna Medical B3 financing was announced on 1 July 2026.
Who are they?
Materna Medical develops OBGYN and pelvic-health devices, including Ellora, which is designed to reduce pelvic floor injury during vaginal delivery.
Geographical focus?
Materna Medical is focused on the United States, with clinical and commercial activity around OBGYN and pelvic health.
Why do we include them in the femtech market?
Materna Medical belongs in the femtech market because its devices target pregnancy, childbirth-related pelvic floor injury and women’s pelvic conditions.
What is the company stage?
Materna Medical is at a late clinical and commercial-readiness stage, with launch preparation underway for Ellora.
How much did they raise?
Materna Medical raised $5.00 million for this round.
What round is it?
The Materna Medical financing was a Series B3, also described as B3 financing.
Why did they raise?
Materna Medical raised to accelerate clinical milestones, manufacturing, commercialization and launch preparation for the Ellora Obstetrical System.
This chart, included in our femtech market deck, compares the main business model options for menopause telehealth platforms
Intu Diagnostics raised about $1.29 million in bridge funding in July 2026
When was it?
The Intu Diagnostics bridge round was announced on 1 July 2026.
Who are they?
Intu Diagnostics is building a simple molecular HPV test cartridge that delivers PCR-quality results without a lab, electricity or trained staff.
Geographical focus?
Intu Diagnostics is based in Germany and is relevant for low-resource cervical cancer screening settings globally.
Why do we include them in the femtech market?
Intu Diagnostics belongs in the femtech market because HPV testing is directly tied to gynecological diagnostics and cervical cancer prevention.
What is the company stage?
Intu Diagnostics is a prototype and pre-commercial diagnostics company preparing for a consumer launch in 2027.
How much did they raise?
Intu Diagnostics raised about $1.29 million, based on the €1.1 million amount reported.
What round is it?
The Intu Diagnostics financing was a bridge round.
Why did they raise?
Intu Diagnostics raised to fund IP protection, pilot manufacturing trials and preparation for a future seed round.
Mila raised $2.5 million in pre-seed funding in July 2026
When was it?
The Mila pre-seed round was announced on 1 July 2026.
Who are they?
Mila makes design-led intimate wellness products, including a 4-in-1 intimate wellness device and hydrating intimate gliding mist.
Geographical focus?
Mila is based in Miami and is focused first on the U.S. consumer intimate wellness market.
Why do we include them in the femtech market?
Mila belongs in the femtech market because its products are designed around women’s intimate wellness and sexual health needs.
What is the company stage?
Mila is an early commercial brand at the pre-seed stage.
How much did they raise?
Mila raised $2.50 million for this round.
What round is it?
The Mila financing was a pre-seed round.
Why did they raise?
Mila raised to build and scale a modern intimate wellness brand for women.
This chart, included in our femtech market deck, shows how Flo Health is capturing share in femtech
Rejoni raised $25 million in financing in July 2026
When was it?
The Rejoni financing was announced on 1 July 2026.
Who are they?
Rejoni is developing Juveena, a uterine hydrogel system placed after intrauterine surgery to support endometrial healing.
Geographical focus?
Rejoni is focused on the U.S. clinical and commercial market for uterine health and gynecologic surgery support.
Why do we include them in the femtech market?
Rejoni belongs in the femtech market because the product targets uterine healing, pelvic health and fertility-adjacent gynecologic care.
What is the company stage?
Rejoni is a clinical-stage company preparing for FDA approval and launch readiness.
How much did they raise?
Rejoni raised $25.00 million for this financing.
What round is it?
The Rejoni round was a financing round, with the exact stage not disclosed in the source.
Why did they raise?
Rejoni raised to scale manufacturing, support market access, engage physicians and patients, and prepare for commercial launch.
Ovum raised $4 million in seed funding in June 2026
When was it?
The Ovum seed round was announced on 24 June 2026.
Who are they?
Ovum builds an AI health journal that helps women track symptoms, reproductive stages, biometrics, medications and medical records.
Geographical focus?
Ovum is focused first on Australia, with a longer-term ambition to build a global women’s health data platform.
Why do we include them in the femtech market?
Ovum belongs in the femtech market because the product is built around female health data, reproductive health, menopause and care advocacy.
What is the company stage?
Ovum is an early-growth company with a live product, more than 20,000 downloads and clinical trials launched.
How much did they raise?
Ovum raised $4.00 million for this seed round.
What round is it?
The Ovum financing was a seed round.
Why did they raise?
Ovum raised to build a women-specific longitudinal dataset, expand AI development, support clinical trials and scale the platform.
In our femtech market deck, we identify pain points entrepreneurs should prioritize
June Health raised about $1.76 million in June 2026
When was it?
The June Health funding round was announced on 18 June 2026.
Who are they?
June Health offers AI-enabled women’s health navigation, care coordination and virtual multidisciplinary care through employers and partners.
Geographical focus?
June Health is focused on Canada, with distribution through employers, benefits partners and strategic institutional channels.
Why do we include them in the femtech market?
June Health belongs in the femtech market because the care model is built around women’s health pathways, including fertility, menopause and hormonal health.
What is the company stage?
June Health is an early-growth B2B benefits platform.
How much did they raise?
June Health raised about $1.76 million, based on the C$2.4 million amount reported.
What round is it?
The June Health financing was a funding round, with the exact stage not disclosed in the source.
Why did they raise?
June Health raised to support AI and data infrastructure, employer partnerships, distribution partnerships and platform expansion.
Clair Health raised $11.6 million in seed funding in June 2026
When was it?
The Clair Health seed round was announced on 17 June 2026.
Who are they?
Clair Health is building a wrist-worn, noninvasive hormone monitor for estrogen, progesterone, LH and FSH.
Geographical focus?
Clair Health is based in San Francisco and is focused on the U.S. women’s hormone monitoring market.
Why do we include them in the femtech market?
Clair Health belongs in the femtech market because the device is built around fertility, menopause and female hormone monitoring.
What is the company stage?
Clair Health is a pre-launch seed-stage company with a large waitlist and a planned November 2026 launch.
How much did they raise?
Clair Health raised $11.60 million for this seed round.
What round is it?
The Clair Health financing was a seed round.
Why did they raise?
Clair Health raised to accelerate the wearable launch and continue research into noninvasive hormone monitoring.
This market map, featured in our femtech market deck, highlights top companies and startups in the femtech market
Dioseve raised about $7 million in extended Series A funding in June 2026
When was it?
The Dioseve extended Series A was announced on 17 June 2026.
Who are they?
Dioseve develops iPS cell-derived ovarian support technology to mature eggs outside the body and reduce the burden of IVF.
Geographical focus?
Dioseve is based in Tokyo and is focused on fertility biotech with relevance for IVF clinics and patients beyond Japan.
Why do we include them in the femtech market?
Dioseve belongs in the femtech market because its lead program targets IVF lab technology and female fertility treatment.
What is the company stage?
Dioseve is a preclinical and clinical-translation biotech company.
How much did they raise?
Dioseve raised about $7.00 million for this extended Series A round.
What round is it?
The Dioseve financing was an extended Series A round.
Why did they raise?
Dioseve raised to accelerate iPS cell-derived co-culture technology and make IVF less physically, emotionally and financially burdensome.
Mammogen raised up to $30 million in Series A funding in June 2026
When was it?
The Mammogen Series A was announced on 10 June 2026.
Who are they?
Mammogen is developing genTRU-breast, an RNA blood test for women with dense breast tissue after mammography.
Geographical focus?
Mammogen is based in Newport Beach and is focused on the U.S. breast health diagnostics market.
Why do we include them in the femtech market?
Mammogen belongs in the femtech market because the test targets breast cancer detection and unnecessary biopsy reduction for women with dense breasts.
What is the company stage?
Mammogen is a clinical validation and pivotal-study stage diagnostics company.
How much did they raise?
Mammogen raised up to $30.00 million for this Series A round.
What round is it?
The Mammogen financing was a Series A round.
Why did they raise?
Mammogen raised to advance genTRU-breast through pivotal study work and toward broader clinical use.
This chart, included in our femtech market deck, shows annual funding in femtech startups
Joyvié Health raised about $1.04 million in pre-seed funding in June 2026
When was it?
The Joyvié Health pre-seed round was announced on 5 June 2026.
Who are they?
Joyvié Health is developing reusable continence underwear that contains stool in a disposable pouch to reduce skin contact and caregiver burden.
Geographical focus?
Joyvié Health is focused first on the UK, including care homes, hospitals, domiciliary care settings and a planned direct-to-consumer launch.
Why do we include them in the femtech market?
Joyvié Health belongs in the femtech market because the product targets pelvic health and continence care with a purpose-built medical garment.
What is the company stage?
Joyvié Health is a pre-seed company at the pilot and pre-launch stage.
How much did they raise?
Joyvié Health raised about $1.04 million, based on the €897,000 amount reported.
What round is it?
The Joyvié Health financing was a pre-seed round.
Why did they raise?
Joyvié Health raised to run clinical pilots, prepare care-setting adoption and support a direct-to-consumer launch.
HealthFab raised about $2.4 million in Series A funding in May 2026
When was it?
The HealthFab Series A was announced on 4 May 2026.
Who are they?
HealthFab sells reusable period underwear and broader menstrual wellness products under the GoPadFree brand.
Geographical focus?
HealthFab is based in Bengaluru and is focused on India through D2C, quick commerce, retail and marketplace channels.
Why do we include them in the femtech market?
HealthFab belongs in the femtech market because the core business is menstrual hygiene, reusable period products and period-care wellness.
What is the company stage?
HealthFab is a growth-stage D2C brand with a large user base and distribution expansion underway.
How much did they raise?
HealthFab raised about $2.40 million, based on the ₹20 crore amount reported.
What round is it?
The HealthFab financing was a Series A round.
Why did they raise?
HealthFab raised to expand its period-care portfolio, scale distribution through quick commerce and retail, and increase manufacturing capacity.
Related blog posts
- How strong is fundraising in the femtech market right now?
- The most recent news in the femtech market
- What is the true size of the femtech market?
- How funding activity has evolved in the femtech market
- What are the key fundraising trends in the femtech market?
- All the funding deals announced in the femtech market
- Which companies have raised the most funding in the femtech market?
- Which companies are the most valued in the femtech market?
